Amneal Pharmaceuticals, Inc. (NYSE:NASDAQ:AMRX) Director Deborah M. Autor sold a total of 38,000 shares of company stock in two separate transactions on May 16 and May 17, according to a recent SEC filing. The transactions amounted to over $256,000 in total value, with share prices ranging from $6.727 to $6.76.
On May 16, Autor sold 14,553 shares at an average price of $6.76 per share. The following day, she sold an additional 23,447 shares at an average price of $6.727. The sales were executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the footnotes of the filing.
Post-transaction, Autor still retains 93,402 shares of Amneal Pharmaceuticals, indicating a continued investment in the company's future. Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, specializes in pharmaceutical preparations and has been a key player in the industry.
Investors often monitor insider transactions as they provide insights into executives' perspectives on the company's stock value and future performance. Autor's recent stock sales represent a significant transaction within the company and may be of interest to current and potential shareholders.
The sales were reported to the Securities and Exchange Commission and were filed under the Form 4 documentation, which is used for the declaration of insider trading activities such as stock purchases and sales by company executives and directors.
InvestingPro Insights
Amneal Pharmaceuticals (NYSE:AMRX) has been drawing attention not only for insider transactions but also for its financial performance and market valuation. According to real-time data from InvestingPro, Amneal has a market capitalization of $2.08 billion, reflecting its position in the pharmaceutical industry. Despite a negative P/E ratio of -8.63, indicating the company was not profitable over the last twelve months, analysts are optimistic as they predict Amneal will be profitable this year.
Investors may find the company's return metrics particularly compelling. Amneal Pharmaceuticals has shown a strong price performance with a one-year total return of 195.24%, and it is currently trading near its 52-week high, at 96.49% of that peak. This performance is underpinned by a substantial six-month price total return of 51.89%, suggesting robust investor confidence in the company's trajectory.
Two InvestingPro Tips that might interest potential investors in Amneal Pharmaceuticals are:
- The valuation implies a strong free cash flow yield, which can be a sign of financial health and the company's ability to sustain and fund operations.
- With a notable revenue growth of 9.82% over the last twelve months as of Q1 2023, Amneal demonstrates its ability to expand its business operations effectively.
For those seeking more in-depth analysis and additional insights, InvestingPro offers more tips on Amneal Pharmaceuticals. There are a total of 10 InvestingPro Tips available that can provide further guidance on investment decisions. To access these insights, visit https://www.investing.com/pro/AMRX and don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.